HotSpot Therapeutics to Present IRF5 Small Molecule Inhibitor Data at FOCIS 2025
核心洞察
HotSpot Therapeutics (搜索) will present preclinical data on selective small molecule IRF5 inhibitors at the 25th Annual FOCIS meeting in Boston on June 25, 2025.
The company's Smart Allostery platform uses computational approaches and AI-driven data mining to identify "natural hotspots" on proteins for drug targeting.
HotSpot is developing a pipeline of novel allosteric therapies for autoimmune diseases (搜索) and cancer (搜索) using their proprietary hotspot-targeting approach.
HotSpot Therapeutics (搜索), a clinical-stage biotechnology company, announced it will present preclinical data from its interferon regulatory factor 5 (搜索) (IRF5) program at the 25th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2025) in Boston. The presentation, titled "Targeting IRF5: Discovery and Preclinical Development of Selective Small Molecule Inhibitors," will take place on June 25, 2025, from 4:00-4:15 PM ET during the Late-Breaking Abstracts session.
Smart Allostery Platform Technology
HotSpot Therapeutics (搜索) is pioneering a new class of allosteric drugs that target naturally occurring pockets on proteins called "natural hotspots." According to the company, these pockets are decisive in controlling a protein's cellular function and have significant potential for new drug discovery by enabling the systematic design of potent and selective small molecules with novel pharmacology.
The company's proprietary Smart Allostery™ platform combines computational approaches and AI-driven data mining of large and diverse data sets to uncover hotspots with tailored pharmacology toolkits and bespoke chemistry. This approach drives the rapid discovery of novel hotspot-targeted small molecules.
Therapeutic Pipeline Development
Leveraging their Smart Allostery platform, HotSpot is building a broad pipeline of novel allosteric therapies for the treatment of autoimmune diseases (搜索) and cancer (搜索). The company focuses on developing oral, small molecule allosteric therapies targeting regulatory sites on proteins identified through their platform.
The IRF5 program represents one component of HotSpot's broader therapeutic development strategy. The interferon regulatory factor 5 (搜索) target is being pursued through the company's systematic approach to identifying and developing selective small molecule inhibitors.
Conference Presentation Details
The FOCIS 2025 presentation will be delivered at the Boston Marriott Copley Place in Salons H-K during the conference's Late-Breaking Abstracts session. The 25th Annual Meeting of the Federation of Clinical Immunology Societies runs from June 24-27, 2025, providing a platform for presenting cutting-edge immunology research and therapeutic developments.